Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Q2 2025 Earnings Presentation
14 slides from Genetic Signatures's earnings presentation, Feb 25, 2025
Slide 1: 1H FY25 Market Update
Genetic Signatures Transforming Molecular Diagnostics “JH FY25 Market Update (26 February 2025
Slide 2: 1H FY25 Market Update
1H FY25 Market Update al use only 2
Slide 3: 1H FY25 Market Update
1H FY25 Market Update • • al use only • • • • • 3
Slide 4: Operational Update
Genetic Signatures Transforming Molecular Diagnostics “Operational Update (126 February 2025
Slide 5: al use only
1H FY25 Market Update • • al use only • • • 5
Slide 6: al use only
1H FY25 Market Update al use only • • • • • 6
Slide 7: Target GI parasite testing segments and potential TAM
1H FY25 Market Update Target GI parasite testing Potential TAM Share of targeted 2.2M segments requirements = 5.5M tests tests by segment High volume LabCorp / Quest = >1500 tests / day 1.6 M 50% al use only Others ~100-300 tests / day 30% of TAM Low to medium volume, Some sites high volume 3.0 M 32
Slide 8: al use only
1H FY25 Market Update • • al use only • • • 88
Slide 9: Financial Highlights
Genetic Signatures Transforming Molecular Diagnostics “Financial Highlights (126 February 2025
Slide 10: al use only
1H FY25 Market Update • • al use only
Slide 11: al use only
1H FY25 Market Update • • al use only • • • 11
Slide 12: al use only
1H FY25 Market Update • al use only • • • 12
Slide 13: al use only
1H FY25 Market Update • • • • al use only • • • • • • • • 13
Slide 14: Contact Us
Contact Us Allison Rossiter al use only Chief Executive Officer E: allison.rossiter@geneticsignatures.com P: +61 (02) 9870 7580 Karl Pechmann Chief Financial & Operating Officer & Joint Company Secretary E: karl.pechmann@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 14